AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24449770 — intervention group
Group type: COMPARATOR
Intervention: Piperaquine without concomitant food
Number of subjects: 30
Study 22964730 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal irrigation with a minimum of 500 mL normal saline
Number of subjects: 220
Study 22964730 — intervention group
Group type: COMPARATOR
Intervention: Suction only
Number of subjects: 220
Study 19686914 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronectomy (case group, n = 102)
Number of subjects: 220
Study 19686914 — intervention group
Group type: COMPARATOR
Intervention: Extraction (control group, n = 118)
Number of subjects: 220
Study 17454698 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 7
Study 17454698 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with a past history of MDD
Number of subjects: 7
Study 17454698 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant treatment
Number of subjects: 7
Study 15455256 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine ER 4 mg once daily
Number of subjects: 293
Study 15455256 — intervention group
Group type: EXPERIMENTAL
Intervention: oxybutynin 3 mg three times daily
Number of subjects: 293
Study 15455256 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 293
Study 12693431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay condition
Number of subjects: 97
Study 12693431 — intervention group
Group type: COMPARATOR
Intervention: No Pay condition
Number of subjects: 97
Study 10204597 — intervention group
Group type: EXPERIMENTAL
Intervention: Female donors, young donors, first-time donors, low-weight donors, and donors with low predonation blood pressure
Number of subjects: 1890
Study 10204597 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, weight, and donation status (first-time or repeat donor)
Number of subjects: 1890
Study 10204597 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex, predonation blood pressure, and predonation pulse
Number of subjects: 1890
Study 8833935 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF patients
Number of subjects: 25
Study 8833935 — intervention group
Group type: COMPARATOR
Intervention: Controls (healthy people with normal renal function)
Number of subjects: 25
Study 2376265 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical photographic records
Number of subjects: 29
Study 2376265 — intervention group
Group type: COMPARATOR
Intervention: Control group (no photographic records)
Number of subjects: 29
Study 7031516 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day bromopride for 15 days
Number of subjects: 16
Study 7031516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31161388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST-PD) for 12 weeks
Number of subjects: 76
Study 31161388 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 76
Study 28181675 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytotherapeutic intervention (containing turmeric, resveratrol, green tea, and broccoli sprouts) for 12 weeks
Number of subjects: 22
Study 28181675 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 22
Study 24870446 — intervention group
Group type: EXPERIMENTAL
Intervention: LAI risperidone (LAI‐R)
Number of subjects: 305
Study 24870446 — intervention group
Group type: COMPARATOR
Intervention: Oral SGAs
Number of subjects: 305
Study 24095230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheilectomy and microfracture procedure (Group A)
Number of subjects: 14
Study 24095230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheilectomy and dorsal crescentic osteotomy (Group B)
Number of subjects: 14
Study 21419437 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneoscopic partial adrenalectomy
Number of subjects: 212
Study 21419437 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneoscopic total adrenalectomy
Number of subjects: 212
Study 18514614 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help cognitive behavioral treatment with minimal therapist contact
Number of subjects: 21
Study 18514614 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 21
Study 17596915 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg dihydrexidine
Number of subjects: 20
Study 17596915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12929472 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers)
Number of subjects: 0
Study 12929472 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antihypertensive agents with diuretics
Number of subjects: 0
Study 12929472 — intervention group
Group type: EXPERIMENTAL
Intervention: Blockade of the renin-angiotensin system
Number of subjects: 0
Study 12929472 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of angiotensin-converting enzyme inhibitor and diuretic as first-line treatment
Number of subjects: 0
Study 11006432 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich, protein-poor food (CR/PP)
Number of subjects: 45
Study 11006432 — intervention group
Group type: COMPARATOR
Intervention: Protein-rich, carbohydrate-poor (PR/CP) diet
Number of subjects: 45
Study 8650997 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐energetic extracorporeal shock wave therapy (1000 impulses, energy density 0.06 mJ/mm2, administered 3 times in weekly intervals)
Number of subjects: 75
Study 8650997 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐energetic extracorporeal shock wave therapy
Number of subjects: 75
Study 1442986 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 43
Study 1442986 — intervention group
Group type: COMPARATOR
Intervention: Animal insulin
Number of subjects: 43
Study 6585839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 2
Study 6585839 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 2
Study 3525431 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme A (2,000 Lipmann U daily) administered intravenously for 20 days
Number of subjects: 27
Study 3525431 — intervention group
Group type: COMPARATOR
Intervention: Sulodexide (300 Lipasemic U daily) administered intravenously for 20 days
Number of subjects: 27
Study 30204554 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PPARγ agonist pioglitazone (45 mg)
Number of subjects: 30
Study 30204554 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 30
Study 27904554 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication treatment (four-drug regimen)
Number of subjects: 49
Study 27904554 — intervention group
Group type: COMPARATOR
Intervention: Placebo (capsules and tablets)
Number of subjects: 49
Study 25066248 — intervention group
Group type: EXPERIMENTAL
Intervention: Antepartum dalteparin (5000 international units once daily up to 20 weeks' gestation, and twice daily thereafter until at least 37 weeks' gestation)
Number of subjects: 292
Study 25066248 — intervention group
Group type: COMPARATOR
Intervention: No antepartum dalteparin (control group)
Number of subjects: 292
Study 25066248 — intervention group
Group type: EXPERIMENTAL
Intervention: Antepartum dalteparin
Number of subjects: 292
Study 24669602 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric aspiration
Number of subjects: 54
Study 24669602 — intervention group
Group type: COMPARATOR
Intervention: No gastric aspiration (Control)
Number of subjects: 54
Study 20574541 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly sulfadoxine‐pyrimethamine (SP)
Number of subjects: 1200
Study 20574541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 18492125 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine alone (100 mg)
Number of subjects: 19
Study 18492125 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg b.i.d. for 11 days) + Etravirine (100 mg on day 8)
Number of subjects: 19
Study 18492125 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (40 mg q.d. for 11 days) + Etravirine (100 mg on day 8)
Number of subjects: 19
Study 16825031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl (30 to 180 mg/day)
Number of subjects: 1136
Study 16825031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1136
Study 16825031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl
Number of subjects: 1136
Study 14688560 — intervention group
Group type: EXPERIMENTAL
Intervention: Height growth velocity
Number of subjects: 494
Study 14688560 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight growth velocity
Number of subjects: 494
Study 14688560 — intervention group
Group type: EXPERIMENTAL
Intervention: Head circumference growth velocity
Number of subjects: 494
Study 14688560 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load
Number of subjects: 494
Study 10780128 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 192
Study 10780128 — intervention group
Group type: COMPARATOR
Intervention: Intensive outpatient treatment
Number of subjects: 192
Study 10780128 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient treatment
Number of subjects: 192
Study 10780128 — intervention group
Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 192
Study 8831956 — intervention group
Group type: EXPERIMENTAL
Intervention: UCS inflation procedure
Number of subjects: 50
Study 8831956 — intervention group
Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 50
Study 1442677 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg triglycyl‐lysin‐vasopressin
Number of subjects: 40
Study 1442677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6363935 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.8 million units of aqueous procaine penicillin plus 1 g of probenecid
Number of subjects: 539
Study 6363935 — intervention group
Group type: EXPERIMENTAL
Intervention: nine tablets of trimethoprim‐sulfamethoxazole daily for three days
Number of subjects: 539
Study 6363935 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of tetracycline four times a day for five days
Number of subjects: 539
Study 30625176 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention including training for healthcare assistants, information and quality circles for general practitioners, and 24 months of case management.
Number of subjects: 736
Study 30625176 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 736
Study 30625176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (case management).
Number of subjects: 736
Study 29455372 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (G1 HP)
Number of subjects: 50
Study 29455372 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% carbamide peroxide (G2 CP)
Number of subjects: 50
Study 27593420 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (n=36) using MyFitnessPal and Fitbit with 12 coaching calls over 6 months
Number of subjects: 54
Study 27593420 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=18) with U.S. Dietary Guidelines and two brief calls
Number of subjects: 54
Study 24821894 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance Facilitation (PF)
Number of subjects: 1016
Study 24821894 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Learning Collaboratives (LLCs)
Number of subjects: 1016
Study 24821894 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance Facilitation + Local Learning Collaboratives (PF + LLC)
Number of subjects: 1016
Study 24821894 — intervention group
Group type: COMPARATOR
Intervention: Control (Performance Feedback + Academic Detailing)
Number of subjects: 1016
Study 22215361 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 0
Study 22215361 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 0
Study 20134319 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous thrombectomy (PT) plus percutaneous coronary intervention (PCI)
Number of subjects: 104
Study 20134319 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 104
Study 18701236 — intervention group
Group type: EXPERIMENTAL
Intervention: NAP SACC intervention
Number of subjects: 114
Study 18701236 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed-intervention)
Number of subjects: 114
Study 16021438 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine 10 mg o.d.
Number of subjects: 174
Study 16021438 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg o.d.
Number of subjects: 174
Study 12964115 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated levels of quinolinic acid (QA) in cerebrospinal fluid (CSF)
Number of subjects: 100
Study 12964115 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated levels of picolinic acid (PA) in cerebrospinal fluid (CSF)
Number of subjects: 100
Study 12964115 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased QArcolon;KA ratio
Number of subjects: 100
Study 12964115 — intervention group
Group type: COMPARATOR
Intervention: Higher concentrations of kynurenic acid (KA) in Malawian children with malaria compared to Vietnamese adults with malaria
Number of subjects: 100
Study 12964115 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated levels of kynurenic acid (KA) in children with CM
Number of subjects: 100
Study 10981241 — intervention group
Group type: EXPERIMENTAL
Intervention: Apothecon warfarin
Number of subjects: 113
Study 10981241 — intervention group
Group type: COMPARATOR
Intervention: DuPont warfarin
Number of subjects: 113
Study 10981241 — intervention group
Group type: EXPERIMENTAL
Intervention: Apothecon warfarin and DuPont warfarin
Number of subjects: 113
Study 8834418 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg oral test dose of haloperidol (HPDL) followed by maintenance doses of 2, 5 to 8, or 10 to 15 mg twice daily for 5 days to achieve low (< 5 ng/ml), medium (10-18 ng/ml), or high (> 25 ng/ml) Css range.
Number of subjects: 92
Study 8834418 — intervention group
Group type: EXPERIMENTAL
Intervention: C24h prediction formula for maintenance dose of HPDL.
Number of subjects: 92
Study 1600051 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate foam (Proctocort) administered rectally
Number of subjects: 0
Study 4017421 — intervention group
Group type: EXPERIMENTAL
Intervention: Losulazine (10 to 30 mg b.i.d.)
Number of subjects: 32
Study 4017421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 4017421 — intervention group
Group type: EXPERIMENTAL
Intervention: Losulazine
Number of subjects: 32
Study 4017421 — intervention group
Group type: COMPARATOR
Intervention: Losulazine and Placebo
Number of subjects: 32
Study 31262343 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive Sensory Stimulation (RSS) for 45 minutes daily plus usual care for 2 weeks
Number of subjects: 40
Study 31262343 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) alone for 2 weeks
Number of subjects: 40
Study 31262343 — intervention group
Group type: EXPERIMENTAL
Intervention: RSS
Number of subjects: 40
Study 29935486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen (800 mg every 6 hours for 24 hours)
Number of subjects: 80
Study 29935486 — intervention group
Group type: COMPARATOR
Intervention: Intravenous acetaminophen (1 g every 6 hours for 24 hours)
Number of subjects: 80
Study 27863809 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg LMTM twice a day
Number of subjects: 891
Study 27863809 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg LMTM twice a day
Number of subjects: 891
Study 27863809 — intervention group
Group type: COMPARATOR
Intervention: Control (4 mg LMTM twice a day)
Number of subjects: 891
Study 25003166 — intervention group
Group type: EXPERIMENTAL
Intervention: Social exclusion (Cyberball paradigm)
Number of subjects: 0
Study 25003166 — intervention group
Group type: COMPARATOR
Intervention: Inclusion (Cyberball paradigm)
Number of subjects: 0
Study 20708391 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA supplementation
Number of subjects: 30
Study 20708391 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 30
Study 20708391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20367560 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based blood pressure measurement protocol (n=89)
Number of subjects: 157
Study 20367560 — intervention group
Group type: COMPARATOR
Intervention: Ordinary office-based hypertension treatment protocol (n=68)
Number of subjects: 157
Study 18477123 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 0
Study 18477123 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy
Number of subjects: 0
Study 15892410 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (end‐tidal concentration 2%)
Number of subjects: 20
Study 15892410 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 20
Study 12699301 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogens
Number of subjects: 0
Study 12699301 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 10626559 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a dose of 3 IU/m2/day (1 mg/m2/day) (n = 35)
Number of subjects: 54
Study 10626559 — intervention group
Group type: COMPARATOR
Intervention: No intervention (n = 19)
Number of subjects: 54
Study 8665546 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone (50-800 mg)
Number of subjects: 10
Study 8665546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2119935 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified amino acids (MAA)
Number of subjects: 20
Study 2119935 — intervention group
Group type: COMPARATOR
Intervention: Standard amino acids (SAA)
Number of subjects: 20
Study 2119935 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MAA and SAA)
Number of subjects: 20
Study 7002480 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg tolmetin sodium daily
Number of subjects: 21
Study 7002480 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg indomethacin daily
Number of subjects: 21
Study 7002480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29742904 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP) treatment modules ordered according to pretreatment strengths
Number of subjects: 18
Study 29742904 — intervention group
Group type: COMPARATOR
Intervention: Unified Protocol (UP) treatment modules ordered according to pretreatment weaknesses
Number of subjects: 18
Study 28846537 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 108
Study 28846537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax AirWay Scope
Number of subjects: 108
Study 28846537 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 108
Study 28846537 — intervention group
Group type: COMPARATOR
Intervention: GlideScope and Pentax compared to Macintosh
Number of subjects: 108
Study 26719805 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy (LTOT) in COPD patients
Number of subjects: 32
Study 26719805 — intervention group
Group type: EXPERIMENTAL
Intervention: No long-term oxygen therapy (no LTOT) in COPD patients
Number of subjects: 32
Study 26719805 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with interstitial lung disease (ILD)
Number of subjects: 32
Study 26719805 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy
Number of subjects: 32
Study 24645324 — intervention group
Group type: EXPERIMENTAL
Intervention: early, enough methylprednisone combined with immunoglobulin
Number of subjects: 568
Study 24645324 — intervention group
Group type: COMPARATOR
Intervention: conventional therapy
Number of subjects: 568
Study 21499747 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A
Number of subjects: 68
Study 21499747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 21499747 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A (in patients with pericranial muscle tenderness)
Number of subjects: 68
Study 21499747 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients with pericranial muscle tenderness)
Number of subjects: 68
Study 18718654 — intervention group
Group type: EXPERIMENTAL
Intervention: Triceram-cpTi
Number of subjects: 96
Study 18718654 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Porcelain Ti-22-cpTi
Number of subjects: 96
Study 18718654 — intervention group
Group type: COMPARATOR
Intervention: Vita Omega 900-Au-Pd alloy (control group)
Number of subjects: 96
Study 18718654 — intervention group
Group type: EXPERIMENTAL
Intervention: Vita Titankeramik-cpTi
Number of subjects: 96
Study 16500361 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 0
Study 16500361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12957222 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (10 mg)
Number of subjects: 7
Study 12957222 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 7
Study 12957222 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) + Isradipine (10 mg)
Number of subjects: 7
Study 12957222 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (10 mg) + Naltrexone (50 mg)
Number of subjects: 7
Study 12957222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 10996336 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PAD
Number of subjects: 42
Study 10996336 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 42
Study 9278834 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms neostigmine
Number of subjects: 60
Study 9278834 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms neostigmine
Number of subjects: 60
Study 9278834 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms neostigmine
Number of subjects: 60